[go: up one dir, main page]

CL2017000806A1 - Compuestos anti-tnf - Google Patents

Compuestos anti-tnf

Info

Publication number
CL2017000806A1
CL2017000806A1 CL2017000806A CL2017000806A CL2017000806A1 CL 2017000806 A1 CL2017000806 A1 CL 2017000806A1 CL 2017000806 A CL2017000806 A CL 2017000806A CL 2017000806 A CL2017000806 A CL 2017000806A CL 2017000806 A1 CL2017000806 A1 CL 2017000806A1
Authority
CL
Chile
Prior art keywords
tnf
tnf compounds
compounds
olfonucleótidos
antisentido
Prior art date
Application number
CL2017000806A
Other languages
English (en)
Inventor
Christopher C Mader
Tiffany L Halo
Sergei Gryaznov
Richard Kang
Weston Daniel
Original Assignee
Exicure Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55653658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017000806(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exicure Inc filed Critical Exicure Inc
Publication of CL2017000806A1 publication Critical patent/CL2017000806A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)

Abstract

<p>EN EL PRESENTE DOCUMENTO, SE PROPORCIONAN OLIGONUCLEÓTIDOS ANTISENTIDO DE TNF-A. SE PROPORCIONAN MÉTODOS DO TRATAMIENTO DE ENFERMEDADES O TRASTORNOS DE TNF-A USANDO LOS OLIGONUCLEÓTIDOS ANTISENTIDO DE TNF-A Y PRODUCTOS RELACIONADOS.</p>
CL2017000806A 2014-10-06 2017-04-04 Compuestos anti-tnf CL2017000806A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462060424P 2014-10-06 2014-10-06

Publications (1)

Publication Number Publication Date
CL2017000806A1 true CL2017000806A1 (es) 2017-12-15

Family

ID=55653658

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000806A CL2017000806A1 (es) 2014-10-06 2017-04-04 Compuestos anti-tnf

Country Status (18)

Country Link
US (3) US10208310B2 (es)
EP (1) EP3204499A4 (es)
JP (1) JP6741673B2 (es)
KR (1) KR20170063949A (es)
CN (1) CN107002081A (es)
AU (1) AU2015328242A1 (es)
BR (1) BR112017007012A2 (es)
CA (1) CA2963931A1 (es)
CL (1) CL2017000806A1 (es)
CO (1) CO2017004314A2 (es)
CR (1) CR20170181A (es)
EA (1) EA201790802A1 (es)
IL (1) IL251508A0 (es)
MX (1) MX2017004448A (es)
PE (1) PE20170694A1 (es)
PH (1) PH12017500601A1 (es)
SG (1) SG11201702656WA (es)
WO (1) WO2016057549A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
AU2014292926B2 (en) 2013-07-25 2020-03-05 Exicure Operating Company Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
WO2015023797A1 (en) 2013-08-13 2015-02-19 Northwestern University Lipophilic nanoparticles for drug delivery
JP6527516B2 (ja) 2013-12-03 2019-06-05 ノースウェスタン ユニバーシティ リポソーム粒子、前述のものを作製する方法及びその使用
US10413565B2 (en) 2014-04-30 2019-09-17 Northwestern University Nanostructures for modulating intercellular communication and uses thereof
CN106535876B (zh) 2014-06-04 2020-09-11 埃克西奎雷股份有限公司 免疫调节剂通过脂质体球形核酸的多价递送以用于预防或治疗应用
SG11201702656WA (en) 2014-10-06 2017-04-27 Exicure Inc Anti-tnf compounds
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
KR20170104550A (ko) * 2015-01-14 2017-09-15 엑시큐어, 인크. 코어 모티프를 갖는 핵산 나노구조
WO2016149323A1 (en) * 2015-03-16 2016-09-22 Exicure, Inc. Immunomodulatory spherical nucleic acids
US10078092B2 (en) 2015-03-18 2018-09-18 Northwestern University Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules
US20190142739A1 (en) * 2016-04-19 2019-05-16 Exicure, Inc. Topical administration of therapeutic agents and oligonucleotide formulations
KR102617833B1 (ko) 2016-05-06 2023-12-27 엑시큐어 오퍼레이팅 컴퍼니 인터류킨 17 수용체 mRNA의 특이적 녹다운을 위한 안티센스 올리고뉴클레오티드 (ASO)를 제시하는 리포좀성 구형 핵산 (SNA) 구축물
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
WO2018201090A1 (en) 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties
AU2018314159A1 (en) 2017-07-13 2020-01-30 Northwestern University General and direct method for preparing oligonucleotide-functionalized metal-organic framework nanoparticles
WO2020219985A1 (en) * 2019-04-26 2020-10-29 Exicure, Inc. Administration of spherical nucleic acids for ophthalmological uses
CN110385427B (zh) * 2019-07-31 2021-10-19 东南大学 一种水溶性纳米粒子及其制备方法和应用
AU2023360513A1 (en) * 2022-09-28 2025-03-27 Ohio State Innovation Foundation Rna complexes and nanostructures for treatment of cancer metastasis

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955589A (en) 1991-12-24 1999-09-21 Isis Pharmaceuticals Inc. Gapped 2' modified oligonucleotides
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
FR2677272B1 (fr) 1991-06-05 1995-03-03 Biovecteurs As Vecteur particulaire a tropisme selectif, procede de preparation et composition pharmaceutique.
US5814666A (en) 1992-04-13 1998-09-29 The United States As Represented By The Department Of Health And Human Services Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents
ATE143730T1 (de) 1992-04-22 1996-10-15 Ecole Polytech Lipidmembranen fur biosensoranwendungen
US5472881A (en) 1992-11-12 1995-12-05 University Of Utah Research Foundation Thiol labeling of DNA for attachment to gold surfaces
US5932536A (en) 1994-06-14 1999-08-03 The Rockefeller University Compositions for neutralization of lipopolysaccharides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
AU3379597A (en) 1996-06-19 1998-01-07 Hybridon, Inc. Modulation of tetraplex formation by chemical modifications of a g4-containing oligonucleotide
US6361944B1 (en) 1996-07-29 2002-03-26 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
ES2287956T3 (es) 1996-07-29 2007-12-16 Nanosphere Inc. Nanoparticulas que tienen oligonucleotidos unidos a las mismas y usos de las mismas.
US6506564B1 (en) 1996-07-29 2003-01-14 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6051698A (en) 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
EP0856579A1 (en) 1997-01-31 1998-08-05 BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH An antisense oligonucleotide preparation method
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6228642B1 (en) 1998-10-05 2001-05-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression
CA2669457C (en) 1999-07-08 2012-10-02 Cap Biotechnology Inc. Calcium-containing structures and methods of making and using the same
US6585947B1 (en) 1999-10-22 2003-07-01 The Board Of Trustess Of The University Of Illinois Method for producing silicon nanoparticles
US6677153B2 (en) 1999-11-29 2004-01-13 Avi Biopharma, Inc. Antisense antibacterial method and composition
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US7083958B2 (en) 2000-11-20 2006-08-01 The Board Of Trustees Of The University Of Illinois Membrane scaffold proteins
CN1474831A (zh) 2000-11-20 2004-02-11 ����ŵ˹������ѧ�йܻ� 膜支架蛋白
GB0111279D0 (en) 2001-05-10 2001-06-27 Nycomed Imaging As Radiolabelled liposomes
AU2002239726A1 (en) 2001-05-25 2002-12-09 Northwestern University Non-alloying core shell nanoparticles
WO2003051278A2 (en) 2001-07-10 2003-06-26 North Carolina State University Nanoparticle delivery vehicle
US20030044354A1 (en) 2001-08-16 2003-03-06 Carpenter Alan P. Gas microsphere liposome composites for ultrasound imaging and ultrasound stimulated drug release
EP3415625A1 (en) 2002-02-01 2018-12-19 Life Technologies Corporation Double-stranded oligonucleotides
TWI266634B (en) 2002-02-06 2006-11-21 Univ Johns Hopkins Non-invasive diagnostic imaging technology for mitochondria dysfunction using radiolabeled lipophilic salts
CA2485989A1 (en) 2002-05-17 2003-11-27 Esperion Therapeutics, Inc. Methods and compositions for the treatment of ischemic reperfusion
WO2004083902A2 (en) 2002-10-25 2004-09-30 Georgia Tech Research Corporation Multifunctional magnetic nanoparticle probes for intracellular molecular imaging and monitoring
US20040158051A1 (en) 2002-11-19 2004-08-12 Mihri Ozkan Mono and dual conjugation of nanostructures and methods of making and using thereof
EP1550458A1 (en) 2003-12-23 2005-07-06 Vectron Therapeutics AG Synergistic liposomal adjuvants
EP1547581A1 (en) 2003-12-23 2005-06-29 Vectron Therapeutics AG Liposomal vaccine for the treatment of human hematological malignancies
EP1718282A4 (en) 2004-01-15 2010-07-14 Sinai School Medicine PROCESS AND COMPOSITIONS FOR IMAGE PRESENTATION
US20080274454A1 (en) 2004-04-07 2008-11-06 Mirkin Chad A Reversible and Chemically Programmable Micelle Assembly With Dna Block-Copolymer Amphiphiles
US7964196B2 (en) 2004-05-25 2011-06-21 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
EP1604669A1 (en) 2004-06-10 2005-12-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of ATP analogues for treatment of cardiovascular diseases
WO2006016978A1 (en) 2004-06-30 2006-02-16 Applera Corporation Analog probe complexes
WO2006044660A2 (en) 2004-10-14 2006-04-27 Vanderbilt University Functionalized solid lipid nanoparticles and methods of making and using same
US8211712B2 (en) 2005-03-29 2012-07-03 The Board Of Trustees Of The Leland Stanford Junior University Method of fabricating lipid bilayer membranes on solid supports
EP1880019A1 (en) 2005-05-12 2008-01-23 Arizona Board Regents, a body corporate of the State of Arizona, acting for and on behalf of Arizona State University Self-assembled nucleic acid nanoarrays and uses therefor
WO2006128121A2 (en) 2005-05-27 2006-11-30 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
WO2006138145A1 (en) 2005-06-14 2006-12-28 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
JP2009500412A (ja) 2005-07-07 2009-01-08 コーリー ファーマシューティカル グループ，インコーポレイテッド 癌の処置のための、抗ｃｔｌａ−４抗体とｃｐｇモチーフ含有合成オリゴデオキシヌクレオチドとの組み合わせ治療
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US20090317802A1 (en) 2005-12-09 2009-12-24 Bhatia Sangeeta N Compositions and Methods to Monitor RNA Delivery to Cells
AU2007210034A1 (en) 2006-01-26 2007-08-09 University Of Massachusetts RNA silencing agents for use in therapy and nanotransporters for efficient delivery of same
WO2007106683A2 (en) 2006-03-10 2007-09-20 The Trustees Of The University Of Pennsylvania Biomimetic iron-oxide-containing lipoprotein and related materials
WO2007137117A2 (en) 2006-05-17 2007-11-29 Massachusetts Institute Of Technology Aptamer-directed drug delivery
US8017237B2 (en) 2006-06-23 2011-09-13 Abbott Cardiovascular Systems, Inc. Nanoshells on polymers
EP2046954A2 (en) 2006-07-31 2009-04-15 Curevac GmbH NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT
AU2007286203B2 (en) 2006-08-08 2013-05-02 Board Of Regents, The University Of Texas System Multistage delivery of active agents
US7976743B2 (en) 2006-10-16 2011-07-12 Northwestern University Gas-containing liposomes
MX2009009127A (es) 2007-02-27 2009-10-19 Univ Northwestern Unión de moléculas a nanopartículas.
EP2118129A4 (en) 2007-03-01 2010-04-28 Life Technologies Corp ISOLATED PHOSPHOLIPID PROTEIN PARTICLES
EP2133097B1 (en) 2007-03-30 2017-01-25 Hirofumi Takeuchi Transpulmonary liposome for controlling drug arrival
US9950830B2 (en) 2007-04-23 2018-04-24 Coldkeepers, Llc Insulated liners and containers
CA2689923A1 (en) 2007-05-30 2008-12-11 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
US20100272813A1 (en) * 2007-07-23 2010-10-28 Aarhus Universitet Nanoparticle-mediated treatment for inflammatory diseases
US8563527B2 (en) 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
EP2209472A1 (en) 2007-10-12 2010-07-28 The University of North Carolina at Chapel Hill Use of nitric oxide to enhance the efficacy of silver and other topical wound care agents
KR101198354B1 (ko) 2007-10-17 2013-03-14 주식회사 삼양바이오팜 핵산 전달용 저밀도 지단백질 유사(ＬＤＬ-ｌｉｋｅ) 양이온성 나노입자, 그의 제조방법 및 이를 이용한 핵산의 전달 방법
MX2010005089A (es) 2007-11-09 2010-05-21 Univ Northeastern Nanoparticulas tipo micela autoensambles para el suministro sistemico de genes.
WO2009073984A1 (en) 2007-12-12 2009-06-18 University Health Network High-density lipoprotein-like peptide-phospholipid scaffold ('hpps') nanoparticles
WO2009089117A1 (en) 2008-01-04 2009-07-16 Hormel Foods Corporation Encapsulation of oxidatively unstable compounds
WO2009105260A2 (en) 2008-02-21 2009-08-27 University Of Kentucky Ultra-small rnas as toll-like receptor-3 antagonists
EP2105145A1 (en) 2008-03-27 2009-09-30 ETH Zürich Method for muscle-specific delivery lipid-conjugated oligonucleotides
WO2009131931A1 (en) 2008-04-21 2009-10-29 3M Innovative Properties Company Nitric oxide-releasing compositions, devices and methods
WO2009131704A2 (en) 2008-04-25 2009-10-29 Northwestern University Nanostructures suitable for sequestering cholesterol and other molecules
US8063131B2 (en) 2008-06-18 2011-11-22 University Of Washington Nanoparticle-amphipol complexes for nucleic acid intracellular delivery and imaging
US20100035967A1 (en) 2008-07-28 2010-02-11 Idera Pharmaceuticals, Inc. Modulation of toll-like receptor 9 expression by antisense oligonucleotides
US8153605B2 (en) 2008-08-04 2012-04-10 Idera Pharmaceuticals, Inc. Modulation of toll-like receptor 3 expression by antisense oligonucleotides
US20100047188A1 (en) 2008-08-04 2010-02-25 Idera Pharmaceuticals, Inc. Modulation of toll-like receptor 8 expression by antisense oligonucleotides
US20130090457A1 (en) 2008-10-31 2013-04-11 Janssen Biotech, Inc. Toll-Like Receptor 3 Antagonists for the Treatment of Metabolic and Cardiovascular Diseases
US9139827B2 (en) 2008-11-24 2015-09-22 Northwestern University Polyvalent RNA-nanoparticle compositions
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
US20100184844A1 (en) 2009-01-08 2010-07-22 Northwestern University Inhibition of Bacterial Protein Production by Polyvalent Oligonucleotide Modified Nanoparticle Conjugates
EP2391717A1 (en) 2009-01-28 2011-12-07 Aarhus Universitet Treatment of radiation-induced fibrosis
AU2010223888A1 (en) 2009-03-13 2011-10-06 Egen, Inc. Compositions and methods for the delivery of biologically active RNAs
KR102036676B1 (ko) 2009-04-15 2019-10-24 노오쓰웨스턴 유니버시티 올리고뉴클레오티드 관능화된 나노입자의 전달
WO2011017382A2 (en) 2009-08-03 2011-02-10 The Regents Of The University Of California Nanofibers and morphology shifting micelles
US20120277283A1 (en) 2009-08-04 2012-11-01 Mirkin Chad A Localized Delivery of Gold Nanoparticles for Therapeutic and Diagnostic Applications
WO2011017690A2 (en) 2009-08-07 2011-02-10 Northwestern University Intracellular delivery of contrast agents with functionalized nanoparticles
US20120244230A1 (en) 2009-09-01 2012-09-27 Massachusetts Institute Of Technology Polyvalent polynucleotide nanoparticle conjugates as delivery vehicles for a chemotherapeutic agent
WO2011028850A1 (en) 2009-09-01 2011-03-10 Northwestern University Delivery of therapeutic agents using oligonucleotide-modified nanoparticles as carriers
KR101132626B1 (ko) 2009-10-12 2012-04-02 주식회사 녹십자 난용성 약물의 전달을 위한 고밀도지단백 나노입자의 제조방법
US20110111974A1 (en) 2009-10-23 2011-05-12 Northwestern University Short Duplex Probes for Enhanced Target Hybridization
CN102666879B (zh) 2009-10-30 2016-02-24 西北大学 模板化的纳米缀合物
US9138418B2 (en) 2009-12-09 2015-09-22 William Marsh Rice University Therapeutic compositions and methods for delivery of active agents cleavably linked to nanoparticles
CA2784547A1 (en) 2009-12-23 2011-06-30 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Influenza targets
WO2011079290A1 (en) 2009-12-24 2011-06-30 Northwestern University Oligonucleotide specific uptake of nanoconjugates
US20130034599A1 (en) 2010-01-19 2013-02-07 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities
EP2399608B1 (en) 2010-03-05 2020-07-08 Sebastian Fuchs Immunomodulating nanoparticulate composition for use in inhalation therapy
US20130101512A1 (en) 2010-03-12 2013-04-25 Chad A. Mirkin Crosslinked polynucleotide structure
CA2795289A1 (en) 2010-04-08 2011-10-13 Sanford-Burnham Medical Research Institute Methods and compositions for enhanced delivery of compounds
KR101198715B1 (ko) 2010-05-14 2012-11-13 한국생명공학연구원 핵산 및 친수성 음이온 화합물의 고효율 포획을 위한 비대칭 리포솜 및 이의 제조방법
US20140134658A1 (en) 2010-05-21 2014-05-15 Notrhwestern University, An Illinois Not For Profit Corporation Psa enzymatic activity: a new biomarker for assessing prostate cancer aggressiveness
US20130089614A1 (en) 2010-06-14 2013-04-11 Xuefeng Zhang Magnetic Nanoparticles and Uses Thereof
GB201014026D0 (en) 2010-08-20 2010-10-06 Ucl Business Plc Treatment
CN103189050B (zh) 2010-10-26 2017-09-29 Ac免疫有限公司 包含通过疏水部分修饰的肽的基于脂质体的构建体
AU2011329668B2 (en) 2010-11-19 2016-07-28 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
CA2824786A1 (en) 2011-01-12 2012-07-19 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
EP3494974B1 (en) 2011-07-08 2023-10-18 The University of North Carolina at Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
WO2013012628A2 (en) 2011-07-15 2013-01-24 The University Of Georgia Research Foundation, Inc. Immune-stimulating photoactive hybrid nanoparticles
JP6170047B2 (ja) 2011-08-31 2017-07-26 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド アポトーシス−ターゲティングナノ粒子
AU2012305715A1 (en) 2011-09-11 2014-04-10 Aurasense, Llc Cellular uptake control systems
JP2015513543A (ja) 2012-02-22 2015-05-14 ノースウェスタン ユニバーシティ 癌および他の状態を処置するためのナノ構造体
US9107904B2 (en) 2012-04-05 2015-08-18 Massachusetts Institute Of Technology Immunostimulatory compositions and methods of use thereof
WO2014025795A1 (en) 2012-08-07 2014-02-13 Northeastern University Compositions for the delivery of rna and drugs into cells
US9095625B2 (en) 2012-08-31 2015-08-04 University Of Massachusetts Graft-copolymer stabilized metal nanoparticles
WO2014120379A1 (en) 2013-01-31 2014-08-07 Privail Inc. Testing device
US9617544B2 (en) * 2013-04-11 2017-04-11 The Board Of Trustees Of The University Of Illinois Nanoparticle mediated delivery of siRNA
AU2014292926B2 (en) 2013-07-25 2020-03-05 Exicure Operating Company Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US20160194642A1 (en) 2013-07-25 2016-07-07 Exicure, Inc Spherical nucleic acid-based constructs as immunoregulatory agents
WO2015023797A1 (en) 2013-08-13 2015-02-19 Northwestern University Lipophilic nanoparticles for drug delivery
JP6527516B2 (ja) 2013-12-03 2019-06-05 ノースウェスタン ユニバーシティ リポソーム粒子、前述のものを作製する方法及びその使用
EP3129391A4 (en) 2014-04-03 2017-12-20 Exicure, Inc. Self assembling nucleic acid nanostructures
CN106535876B (zh) 2014-06-04 2020-09-11 埃克西奎雷股份有限公司 免疫调节剂通过脂质体球形核酸的多价递送以用于预防或治疗应用
TW201620526A (zh) 2014-06-17 2016-06-16 愛羅海德研究公司 用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
SG11201702656WA (en) 2014-10-06 2017-04-27 Exicure Inc Anti-tnf compounds
WO2016085986A1 (en) 2014-11-24 2016-06-02 Northwestern University High density lipoprptein nanoparticles for inflammation
US9397424B2 (en) 2014-11-25 2016-07-19 Tyco Electronics Corporation Connector assembly for electrically coupling a module card to a circuit board
EP3240224B1 (en) 2014-12-23 2019-08-28 LG Electronics Inc. Method for transceiving enhanced physical downlink control channel in wireless access system supporting unlicensed band, and device supporting same
KR20170104550A (ko) 2015-01-14 2017-09-15 엑시큐어, 인크. 코어 모티프를 갖는 핵산 나노구조
WO2016134104A1 (en) 2015-02-18 2016-08-25 Exicure, Inc. Immuno-regulatory lipid containing spherical nucleic acids
WO2016149323A1 (en) 2015-03-16 2016-09-22 Exicure, Inc. Immunomodulatory spherical nucleic acids
US10078092B2 (en) 2015-03-18 2018-09-18 Northwestern University Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules
WO2017011662A1 (en) 2015-07-14 2017-01-19 Exicure, Inc. Spherical nucleic acid (sna)-mediated delivery of lipid-complexes to cells
WO2017011618A1 (en) 2015-07-15 2017-01-19 The Curators Of The University Of Missouri Targeted nanoparticle conjugate and method for co-delivery of sirna and drug
EP3340967B1 (en) 2015-08-24 2024-05-22 Halo-Bio Rnai Therapeutics, Inc. Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
US20170240960A1 (en) 2016-02-24 2017-08-24 Aurasense, Llc Spherical nucleic acids (sna) flare based fluorescence in situ hybridization
US20190142739A1 (en) 2016-04-19 2019-05-16 Exicure, Inc. Topical administration of therapeutic agents and oligonucleotide formulations
US10967072B2 (en) 2016-04-27 2021-04-06 Northwestern University Short interfering RNA templated lipoprotein particles (siRNA-TLP)
WO2017193081A1 (en) 2016-05-06 2017-11-09 Exicure, Inc. Spherical nucleic acid tlr9 agonists
TW201808283A (zh) 2016-08-05 2018-03-16 廣東東陽光藥業有限公司 含氮三環化合物及其在藥物中的應用
EP3500443A4 (en) 2016-08-22 2020-04-15 Stemco Products, Inc. INDEPENDENT TRIANGULAR DOUBLE ARM TRAILER SUSPENSION
WO2019168558A1 (en) 2018-02-28 2019-09-06 Exicure, Inc. Liposomal spherical nucleic acid (sna) constructs for survival of motor neuron (sma) inhibitors
US20210002640A1 (en) 2018-02-28 2021-01-07 Exicure, Inc. Liposomal spherical nucleic acid (sna) constructs for survival of motor neuron (sma) inhibitors
WO2019246409A1 (en) 2018-06-20 2019-12-26 Exicure, Inc. Il-1 beta targeting spherical nucleic acids

Also Published As

Publication number Publication date
CO2017004314A2 (es) 2017-07-28
EP3204499A1 (en) 2017-08-16
BR112017007012A2 (pt) 2018-03-06
JP6741673B2 (ja) 2020-08-19
EP3204499A4 (en) 2018-04-25
JP2017531451A (ja) 2017-10-26
AU2015328242A1 (en) 2017-04-27
US10760080B2 (en) 2020-09-01
US20190211338A1 (en) 2019-07-11
MX2017004448A (es) 2017-10-23
US10208310B2 (en) 2019-02-19
CR20170181A (es) 2017-05-31
SG11201702656WA (en) 2017-04-27
PE20170694A1 (es) 2017-05-26
PH12017500601A1 (en) 2017-09-25
KR20170063949A (ko) 2017-06-08
CA2963931A1 (en) 2016-04-14
CN107002081A (zh) 2017-08-01
US20170306331A1 (en) 2017-10-26
IL251508A0 (en) 2017-05-29
WO2016057549A1 (en) 2016-04-14
US20200339996A1 (en) 2020-10-29
EA201790802A1 (ru) 2017-08-31

Similar Documents

Publication Publication Date Title
CL2017000806A1 (es) Compuestos anti-tnf
JOP20200192A1 (ar) أجسام مضادة لـ tigit
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
BR112017013176A2 (pt) receptores de antígenos quiméricos e métodos para usá-los
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
EP3263132C0 (en) Composition for treating il-6-related diseases
DK3302519T3 (da) Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom
LT3377094T (lt) Susilpninto virulentiškumo bakterijos, skirtos piktybinių solidinių navikų gydymui
DE112015002229A5 (de) Formulierungen zur Behandlung von Hyperthyreose
BR112016015712A2 (pt) método de tratamento de doenças hepáticas.
MA54630A (fr) N,n-bis-2-mercaptoéthyle isophtalamide pour le traitment des maladies neurodégénératives
ME03056B (me) Jedinjenja 3,4-diamino-6-hloropirazin-2-karboksamida za tretman bolesti posredovanih sa enac
AR120118A2 (es) Anticuerpos anti tigit
UA96859U (uk) Застосування рослинного збору &#34;дента-фіт&#34; для лікування запальних захворювань пародонта
BR112016029044A2 (pt) ácido 2-(2-metilamino-pirimidin-4-il)-1h-indol-5-carboxílico [(s)-1-carbamoil-2-(fenil-pirimi¬din-2-il-amino)-etil]-amida para utilização no tratamento de dor associada à osteoartrite